Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2641 to 2655 of 8933 results

  1. 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]

    In development Reference number: GID-TA11635 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  2. Aggressive behaviour in people receiving NHS or social care

    In development Reference number: GID-QS10196 Expected publication date:  28 January 2027

    Quality standard
    In development

  3. Aggressive behaviour in people receiving NHS or social care: prevention and management

    In development Reference number: GID-NG10432 Expected publication date:  28 January 2027

    NICE guideline
    In development

  4. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]

    In development Reference number: GID-HST10063 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  5. Gender Incongruence Services for Children and Young People

    In development Reference number: GID-QS10193 Expected publication date:  02 December 2026

    Quality standard
    In development

  6. Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]

    Awaiting development Reference number: GID-TA11841 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

    In development Reference number: GID-TA11058 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ectopic pregnancy and miscarriage: diagnosis and initial management (update)

    In development Reference number: GID-NG10444 Expected publication date:  06 May 2026

    NICE guideline
    In development

  9. Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

    In development Reference number: GID-TA11130 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Atogepant for treating migraine [ID6615]

    In development Reference number: GID-TA11817 Expected publication date:  09 July 2026

    Technology appraisal guidance
    In development

  11. Bictegravir–lenacapavir for treating HIV-1 [ID6744]

    Awaiting development Reference number: GID-TA11970 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348]

    Awaiting development Reference number: GID-TA11971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Dostarlimab for untreated locally advanced rectal cancer with high microsatellite instability or mismatch repair deficiency [TSID12351]

    Awaiting development Reference number: GID-TA11972 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Elacestrant with everolimus for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [TSID12349]

    Awaiting development Reference number: GID-TA11973 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Tucatinib with trastuzumab and oxaliplatin-based chemotherapy for untreated HER2-positive metastatic or unresectable colorectal cancer [TSID12353]

    Awaiting development Reference number: GID-TA11974 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development